EICHOR
● Completed
Study of GS-3242 in Participants With HIV-1; Substudy-05
Condition: HIV-1-infection · Sponsor: Gilead Sciences
About this study
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (28)
| Franco Felizarta, MD | Bakersfield, California, United States | — |
| Ruane Clinical Research Group, Inc | Los Angeles, California, United States | — |
| Mills Clinical Research | Los Angeles, California, United States | — |
| Quest Clinical Research | San Francisco, California, United States | — |
| Washington Health Institute | Washington D.C., District of Columbia, United States | — |
| Midland Florida Clinical Research Center, LLC | DeLand, Florida, United States | — |
| AIDS Healthcare Foundation - Northpoint | Fort Lauderdale, Florida, United States | — |
| Midway Immunology & Research Center, LLC | Ft. Pierce, Florida, United States | — |
| BLISS Health | Orlando, Florida, United States | — |
| Orlando Immunology Center, PA | Orlando, Florida, United States | — |
| Triple O Research Institute, P.A. | West Palm Beach, Florida, United States | — |
| Chatham County Health Department | Savannah, Georgia, United States | — |
+ 16 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07001319